Infectious Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product & Service (Assays, Kits, & Reagents, Instruments, Services & Software), By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others), By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others), By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others), By Region and Competition
The Global Infectious Disease Testing Market has reached a valuation of USD 34.09 Billion in 2022 and is poised for significant growth, with an expected Compound Annual Growth Rate (CAGR) of 7.17% through 2028. Infectious diseases are caused by a variety of microorganisms, including bacteria, parasites, viruses, and fungi. The identification and characterization of these diseases fall within the realm of infectious disease diagnostics. Healthcare professionals primarily rely on patients' symptoms and physical examinations to detect infectious infections. In addition, a range of laboratory tests is conducted to determine the causative agents, enabling healthcare providers to administer appropriate medical treatments. Pathogens can be transmitted through various means, including direct contact, contaminated water or food, aerosolization of infected particles in the environment, and through vectors like insects (such as mosquitoes) and ticks.
Individuals with compromised immune systems are particularly susceptible to certain infections. This includes individuals undergoing cancer treatment, recent organ transplant recipients, those who have not been vaccinated against common infectious diseases, healthcare workers, and individuals traveling to high-risk areas with mosquito-borne pathogens such as malaria and dengue fever. Doctors employ a variety of laboratory tests to diagnose infectious disorders in these individuals.
Key Market Drivers
Increasing Prevalence of Infectious Diseases
The global infectious disease testing market is experiencing significant growth due to the increasing prevalence of infectious diseases worldwide. The persistent emergence and re-emergence of infectious diseases have heightened the demand for accurate and timely diagnostic solutions. Outbreaks of diseases like COVID-19, Ebola, Zika, and antibiotic-resistant bacterial infections have underscored the need for rapid and efficient testing methods to detect, track, and manage these diseases. Additionally, the globalization of travel and trade has facilitated the rapid spread of infectious agents across borders, making early detection and containment crucial to prevent outbreaks. This has driven up the demand for robust infectious disease testing infrastructure, including diagnostic assays, testing equipment, and surveillance systems.
Furthermore, the aging global population is more susceptible to infectious diseases, particularly due to compromised immune systems. As a result, there is a heightened focus on early detection and monitoring of infections in elderly individuals, contributing to market growth.
The rising awareness among healthcare professionals and the general public about the importance of early diagnosis and prompt treatment has also fueled demand. Timely infectious disease testing not only aids in better patient care but also helps in preventing the spread of diseases within communities. The increasing prevalence of infectious diseases, coupled with the need for rapid and accurate diagnosis, has led to substantial growth in the global infectious disease testing market. As infectious disease threats continue to evolve, the market is expected to further expand, with ongoing advancements in testing technologies and increased investment in public health infrastructure playing pivotal roles in addressing these global health challenges.
Shift in Focus from Centralized Laboratories to Decentralized Point-of-Care Testing
The global infectious disease testing market is undergoing a significant transformation due to a shift in focus from centralized laboratories to decentralized point-of-care testing (POCT). Infectious diseases can spread quickly, and timely diagnosis is crucial for effective containment and treatment. Decentralized testing allows healthcare providers to obtain results within minutes to hours, as opposed to waiting for samples to be transported to and processed in centralized laboratories, which can take days. Another significant factor is improved patient access to healthcare. POCT allows testing to be performed in various settings, including primary care clinics, emergency rooms, pharmacies, and even at home. This accessibility is particularly valuable in underserved or remote areas where centralized laboratories may be less accessible.
Furthermore, the adoption of POCT reduces the burden on centralized laboratories, which can become overwhelmed during outbreaks or pandemics. This decentralized approach helps distribute the testing workload, making it more manageable and efficient for healthcare systems. The global infectious disease testing market is experiencing significant growth due to the shift in focus from centralized laboratories to decentralized point-of-care testing. This transformation is driven by the need for rapid results, improved patient access to testing, pandemic response requirements, and technological advancements. As the healthcare industry continues to embrace POCT, it is likely to play an increasingly critical role in infectious disease diagnostics and management.
Research on Infectious Disease Diagnostics
Ongoing research is leading to the development of more accurate, sensitive, and rapid diagnostic technologies. Molecular diagnostic techniques, such as PCR and next-generation sequencing, are continuously evolving, enabling the detection of infectious agents with high precision. These advancements contribute to the expansion of the market as healthcare providers seek state-of-the-art diagnostic tools. Research into infectious disease diagnostics extends to the fields of surveillance and epidemiology. Advanced diagnostic tools are vital for tracking the prevalence, transmission, and evolution of pathogens. This research is fundamental for public health responses, including vaccination campaigns and outbreak control, thus boosting the market's growth. Research in infectious disease diagnostics often involves global collaborations among governments, healthcare organizations, academic institutions, and pharmaceutical companies. These partnerships accelerate the development and adoption of innovative diagnostic solutions, further expanding the market's reach.
Research-driven advancements in infectious disease diagnostics are pivotal in increasing the global infectious disease testing market. The pursuit of more accurate, efficient, and accessible diagnostic tools is crucial for early detection, effective treatment, and public health responses. As research continues to address the evolving landscape of infectious diseases, we can expect further growth and innovation in this critical healthcare sector.
Technological Advancement in Advanced Diagnostic Technologies
Technological advancements have led to the development of highly sensitive and specific diagnostic assays. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid sequencing, now offer unparalleled precision in detecting infectious agents. This increased accuracy ensures reliable and early disease detection, which is critical for effective treatment and containment. The demand for rapid infectious disease testing has grown significantly, driven by technological innovations that enable quick results. Point-of-care testing (POCT) devices and rapid antigen tests provide results within minutes, allowing for immediate decision-making in clinical settings, public health emergencies, and travel-related testing.
Automation in diagnostic laboratories has improved testing throughput and reduced the risk of errors. High-throughput automated systems can process a large volume of samples efficiently, making them essential for large-scale testing during outbreaks or pandemics. Technological advancements in advanced diagnostic technologies are revolutionizing infectious disease testing by improving accuracy, speed, and accessibility. These innovations are not only meeting the current demands of healthcare but also providing essential tools for responding to emerging infectious threats and improving patient care globally. As technology continues to evolve, the demand for advanced infectious disease testing is likely to increase further.
Key Market Challenges
Inadequate Reimbursements
Inadequate reimbursements within healthcare systems can indeed have a negative impact on the demand for global infectious disease testing. Reimbursements play a critical role in healthcare economics, affecting both healthcare providers and patients. When reimbursement rates for infectious disease testing are insufficient, healthcare providers, including hospitals, clinics, and laboratories, may struggle to cover the costs associated with testing. This financial strain can lead to reduced investment in testing infrastructure, limited availability of testing services, and even closures of diagnostic facilities in underserved areas.
Inadequate reimbursement rates can deter healthcare providers from offering a comprehensive range of infectious disease testing services. This may result in reduced access to critical diagnostic tests, leaving patients with limited options for early disease detection and management. Lower reimbursement rates can discourage laboratories and diagnostic companies from investing in research and development to improve testing accuracy, speed, and accessibility. This can stifle innovation and hinder the development of more advanced and cost-effective testing solutions. Reduced access to infectious disease testing due to inadequate reimbursements can exacerbate healthcare disparities, disproportionately affecting underserved populations. These disparities can result in delayed diagnoses and poorer health outcomes in vulnerable communities.
Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
The rising costs of healthcare present a significant challenge to the adoption and utilization of novel diagnostic techniques for infectious diseases, thereby decreasing the demand for global infectious disease testing. Healthcare systems worldwide are grappling with increasing costs, including personnel, infrastructure, and medication. The allocation of budgets for novel diagnostic technologies often competes with other essential healthcare expenditures, making it difficult to justify the investment in cutting-edge testing methods. Many novel diagnostic techniques, such as advanced molecular testing platforms, require expensive equipment and specialized laboratory infrastructure. Acquiring, maintaining, and operating this equipment can strain healthcare budgets, particularly in resource-limited settings. Healthcare costs can exacerbate economic disparities, with individuals in lower-income brackets facing greater barriers to accessing advanced infectious disease testing. This can result in delayed diagnoses and treatment, increasing the risk of disease transmission.
Key Market Trends
Point-of-Care Testing (POCT)
POCT devices that offer rapid results and can be used outside traditional healthcare settings will continue to gain popularity. They are especially valuable in resource-limited and remote areas. POCT devices are designed to be user-friendly and portable, making them accessible even in areas with limited healthcare infrastructure. They can be used in remote clinics, field hospitals, and rural communities, bringing essential diagnostic capabilities closer to patients.
In resource-limited and remote areas, access to centralized laboratories for traditional testing can be challenging. POCT devices offer the advantage of providing immediate results, allowing healthcare providers to diagnose and initiate treatment promptly. This is crucial for managing infectious diseases effectively and preventing their spread. Rapid results from POCT devices mean that patients do not have to wait for days or weeks to receive their test results. This helps alleviate anxiety, enables timely medical decisions, and improves patient satisfaction. POCT devices often require lower initial investments compared to establishing and maintaining a fully equipped laboratory. This cost-effectiveness is particularly valuable for healthcare facilities with limited budgets.
Telemedicine
The expansion of telemedicine and remote healthcare services will increase the demand for home-based testing kits and virtual consultations with healthcare providers for infectious disease testing and monitoring. Telemedicine allows patients to access healthcare from the comfort of their homes, eliminating the need for travel and reducing wait times. Home-based testing kits align with this convenience, offering a streamlined way for patients to self-administer tests without visiting a healthcare facility. Patients with infectious diseases can benefit from continuous monitoring of their condition. Home-based testing kits enable patients to collect samples at various intervals, while virtual consultations allow healthcare providers to assess results and provide guidance on managing the disease remotely. During outbreaks or pandemics, minimizing in-person interactions can help reduce the risk of disease transmission. Telemedicine and home-based testing allow patients to receive necessary care and diagnostic services while maintaining physical distancing.
Home-based testing data can be aggregated and anonymized to contribute to public health surveillance efforts. Patterns and trends in infectious disease data can help authorities monitor outbreaks and allocate resources more effectively.
Segmental Insights
Product & Service Insights
The reagents segment holds the largest market share in infectious disease molecular diagnostics, driven by the introduction and commercialization of new reagents and their high adoption rate compared to instruments. The demand for PCR reagents has led to a significant increase in novel reagent launches. For instance, in March 2021, PCR Biosystems launched IsoFast Bst Polymerase reagents, enabling faster testing procedures through sensitive, robust, and rapid amplification of RNA & DNA.
The instrument segment is expected to experience lucrative growth during the forecast period. Major players are adopting the strategy of acquiring companies to expand their portfolio in this segment. For example, in March 2021, Roche announced the acquisition of GenMark Diagnostics, a multiplex molecular diagnostics company, for USD 1.8 billion. This acquisition aligns with Roche's infectious disease molecular diagnostics portfolio expansion strategy, ensuring continuous revenue generation and improved patient care in the years to come.
End User Insights
The Diagnostic Reference Laboratories segment emerged as the dominant player in the market for infectious disease molecular diagnostics, capturing the largest revenue share in 2022. This can be attributed to the high procedure volumes and extensive market penetration achieved by this segment. Furthermore, the market for infectious disease molecular diagnostics is expected to witness significant growth due to the increasing number of government initiatives aimed at providing various services, including diagnostic test reimbursements. These proactive measures by the government are anticipated to further propel the demand for infectious disease molecular diagnostics, thereby driving the overall market growth.
Regional Insights
During the projected period, the Global Infectious Disease Diagnostics Market was dominated by North America. This can be attributed to factors such as rapid urbanization, increased investments by healthcare providers in infrastructure improvement, the need to manage the growing burden of infectious diseases, and government initiatives to improve accessibility of diagnostic services. Europe followed closely behind. Furthermore, changing regulatory requirements for infectious disease testing in the general public contributed to the market's expansion. Moreover, advancements in technology have facilitated the integration of previously manual processes, resulting in the establishment of fully automated systems. As a result, it is anticipated that the Infectious Disease Diagnostics Market in this region will witness substantial growth.
Key Market Players
Biomйrieux SA
Abbott Laboratories Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories Inc.
Danaher Corporation
F. Hoffmann-La Roche AG
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Quidel Corporation
Trinity Biotech PLC
Report Scope:
In this report, the Global Infectious Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Infectious Disease Testing Market.
Available Customizations:
Global Infectious Disease Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Individuals with compromised immune systems are particularly susceptible to certain infections. This includes individuals undergoing cancer treatment, recent organ transplant recipients, those who have not been vaccinated against common infectious diseases, healthcare workers, and individuals traveling to high-risk areas with mosquito-borne pathogens such as malaria and dengue fever. Doctors employ a variety of laboratory tests to diagnose infectious disorders in these individuals.
Key Market Drivers
Increasing Prevalence of Infectious Diseases
The global infectious disease testing market is experiencing significant growth due to the increasing prevalence of infectious diseases worldwide. The persistent emergence and re-emergence of infectious diseases have heightened the demand for accurate and timely diagnostic solutions. Outbreaks of diseases like COVID-19, Ebola, Zika, and antibiotic-resistant bacterial infections have underscored the need for rapid and efficient testing methods to detect, track, and manage these diseases. Additionally, the globalization of travel and trade has facilitated the rapid spread of infectious agents across borders, making early detection and containment crucial to prevent outbreaks. This has driven up the demand for robust infectious disease testing infrastructure, including diagnostic assays, testing equipment, and surveillance systems.
Furthermore, the aging global population is more susceptible to infectious diseases, particularly due to compromised immune systems. As a result, there is a heightened focus on early detection and monitoring of infections in elderly individuals, contributing to market growth.
The rising awareness among healthcare professionals and the general public about the importance of early diagnosis and prompt treatment has also fueled demand. Timely infectious disease testing not only aids in better patient care but also helps in preventing the spread of diseases within communities. The increasing prevalence of infectious diseases, coupled with the need for rapid and accurate diagnosis, has led to substantial growth in the global infectious disease testing market. As infectious disease threats continue to evolve, the market is expected to further expand, with ongoing advancements in testing technologies and increased investment in public health infrastructure playing pivotal roles in addressing these global health challenges.
Shift in Focus from Centralized Laboratories to Decentralized Point-of-Care Testing
The global infectious disease testing market is undergoing a significant transformation due to a shift in focus from centralized laboratories to decentralized point-of-care testing (POCT). Infectious diseases can spread quickly, and timely diagnosis is crucial for effective containment and treatment. Decentralized testing allows healthcare providers to obtain results within minutes to hours, as opposed to waiting for samples to be transported to and processed in centralized laboratories, which can take days. Another significant factor is improved patient access to healthcare. POCT allows testing to be performed in various settings, including primary care clinics, emergency rooms, pharmacies, and even at home. This accessibility is particularly valuable in underserved or remote areas where centralized laboratories may be less accessible.
Furthermore, the adoption of POCT reduces the burden on centralized laboratories, which can become overwhelmed during outbreaks or pandemics. This decentralized approach helps distribute the testing workload, making it more manageable and efficient for healthcare systems. The global infectious disease testing market is experiencing significant growth due to the shift in focus from centralized laboratories to decentralized point-of-care testing. This transformation is driven by the need for rapid results, improved patient access to testing, pandemic response requirements, and technological advancements. As the healthcare industry continues to embrace POCT, it is likely to play an increasingly critical role in infectious disease diagnostics and management.
Research on Infectious Disease Diagnostics
Ongoing research is leading to the development of more accurate, sensitive, and rapid diagnostic technologies. Molecular diagnostic techniques, such as PCR and next-generation sequencing, are continuously evolving, enabling the detection of infectious agents with high precision. These advancements contribute to the expansion of the market as healthcare providers seek state-of-the-art diagnostic tools. Research into infectious disease diagnostics extends to the fields of surveillance and epidemiology. Advanced diagnostic tools are vital for tracking the prevalence, transmission, and evolution of pathogens. This research is fundamental for public health responses, including vaccination campaigns and outbreak control, thus boosting the market's growth. Research in infectious disease diagnostics often involves global collaborations among governments, healthcare organizations, academic institutions, and pharmaceutical companies. These partnerships accelerate the development and adoption of innovative diagnostic solutions, further expanding the market's reach.
Research-driven advancements in infectious disease diagnostics are pivotal in increasing the global infectious disease testing market. The pursuit of more accurate, efficient, and accessible diagnostic tools is crucial for early detection, effective treatment, and public health responses. As research continues to address the evolving landscape of infectious diseases, we can expect further growth and innovation in this critical healthcare sector.
Technological Advancement in Advanced Diagnostic Technologies
Technological advancements have led to the development of highly sensitive and specific diagnostic assays. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid sequencing, now offer unparalleled precision in detecting infectious agents. This increased accuracy ensures reliable and early disease detection, which is critical for effective treatment and containment. The demand for rapid infectious disease testing has grown significantly, driven by technological innovations that enable quick results. Point-of-care testing (POCT) devices and rapid antigen tests provide results within minutes, allowing for immediate decision-making in clinical settings, public health emergencies, and travel-related testing.
Automation in diagnostic laboratories has improved testing throughput and reduced the risk of errors. High-throughput automated systems can process a large volume of samples efficiently, making them essential for large-scale testing during outbreaks or pandemics. Technological advancements in advanced diagnostic technologies are revolutionizing infectious disease testing by improving accuracy, speed, and accessibility. These innovations are not only meeting the current demands of healthcare but also providing essential tools for responding to emerging infectious threats and improving patient care globally. As technology continues to evolve, the demand for advanced infectious disease testing is likely to increase further.
Key Market Challenges
Inadequate Reimbursements
Inadequate reimbursements within healthcare systems can indeed have a negative impact on the demand for global infectious disease testing. Reimbursements play a critical role in healthcare economics, affecting both healthcare providers and patients. When reimbursement rates for infectious disease testing are insufficient, healthcare providers, including hospitals, clinics, and laboratories, may struggle to cover the costs associated with testing. This financial strain can lead to reduced investment in testing infrastructure, limited availability of testing services, and even closures of diagnostic facilities in underserved areas.
Inadequate reimbursement rates can deter healthcare providers from offering a comprehensive range of infectious disease testing services. This may result in reduced access to critical diagnostic tests, leaving patients with limited options for early disease detection and management. Lower reimbursement rates can discourage laboratories and diagnostic companies from investing in research and development to improve testing accuracy, speed, and accessibility. This can stifle innovation and hinder the development of more advanced and cost-effective testing solutions. Reduced access to infectious disease testing due to inadequate reimbursements can exacerbate healthcare disparities, disproportionately affecting underserved populations. These disparities can result in delayed diagnoses and poorer health outcomes in vulnerable communities.
Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
The rising costs of healthcare present a significant challenge to the adoption and utilization of novel diagnostic techniques for infectious diseases, thereby decreasing the demand for global infectious disease testing. Healthcare systems worldwide are grappling with increasing costs, including personnel, infrastructure, and medication. The allocation of budgets for novel diagnostic technologies often competes with other essential healthcare expenditures, making it difficult to justify the investment in cutting-edge testing methods. Many novel diagnostic techniques, such as advanced molecular testing platforms, require expensive equipment and specialized laboratory infrastructure. Acquiring, maintaining, and operating this equipment can strain healthcare budgets, particularly in resource-limited settings. Healthcare costs can exacerbate economic disparities, with individuals in lower-income brackets facing greater barriers to accessing advanced infectious disease testing. This can result in delayed diagnoses and treatment, increasing the risk of disease transmission.
Key Market Trends
Point-of-Care Testing (POCT)
POCT devices that offer rapid results and can be used outside traditional healthcare settings will continue to gain popularity. They are especially valuable in resource-limited and remote areas. POCT devices are designed to be user-friendly and portable, making them accessible even in areas with limited healthcare infrastructure. They can be used in remote clinics, field hospitals, and rural communities, bringing essential diagnostic capabilities closer to patients.
In resource-limited and remote areas, access to centralized laboratories for traditional testing can be challenging. POCT devices offer the advantage of providing immediate results, allowing healthcare providers to diagnose and initiate treatment promptly. This is crucial for managing infectious diseases effectively and preventing their spread. Rapid results from POCT devices mean that patients do not have to wait for days or weeks to receive their test results. This helps alleviate anxiety, enables timely medical decisions, and improves patient satisfaction. POCT devices often require lower initial investments compared to establishing and maintaining a fully equipped laboratory. This cost-effectiveness is particularly valuable for healthcare facilities with limited budgets.
Telemedicine
The expansion of telemedicine and remote healthcare services will increase the demand for home-based testing kits and virtual consultations with healthcare providers for infectious disease testing and monitoring. Telemedicine allows patients to access healthcare from the comfort of their homes, eliminating the need for travel and reducing wait times. Home-based testing kits align with this convenience, offering a streamlined way for patients to self-administer tests without visiting a healthcare facility. Patients with infectious diseases can benefit from continuous monitoring of their condition. Home-based testing kits enable patients to collect samples at various intervals, while virtual consultations allow healthcare providers to assess results and provide guidance on managing the disease remotely. During outbreaks or pandemics, minimizing in-person interactions can help reduce the risk of disease transmission. Telemedicine and home-based testing allow patients to receive necessary care and diagnostic services while maintaining physical distancing.
Home-based testing data can be aggregated and anonymized to contribute to public health surveillance efforts. Patterns and trends in infectious disease data can help authorities monitor outbreaks and allocate resources more effectively.
Segmental Insights
Product & Service Insights
The reagents segment holds the largest market share in infectious disease molecular diagnostics, driven by the introduction and commercialization of new reagents and their high adoption rate compared to instruments. The demand for PCR reagents has led to a significant increase in novel reagent launches. For instance, in March 2021, PCR Biosystems launched IsoFast Bst Polymerase reagents, enabling faster testing procedures through sensitive, robust, and rapid amplification of RNA & DNA.
The instrument segment is expected to experience lucrative growth during the forecast period. Major players are adopting the strategy of acquiring companies to expand their portfolio in this segment. For example, in March 2021, Roche announced the acquisition of GenMark Diagnostics, a multiplex molecular diagnostics company, for USD 1.8 billion. This acquisition aligns with Roche's infectious disease molecular diagnostics portfolio expansion strategy, ensuring continuous revenue generation and improved patient care in the years to come.
End User Insights
The Diagnostic Reference Laboratories segment emerged as the dominant player in the market for infectious disease molecular diagnostics, capturing the largest revenue share in 2022. This can be attributed to the high procedure volumes and extensive market penetration achieved by this segment. Furthermore, the market for infectious disease molecular diagnostics is expected to witness significant growth due to the increasing number of government initiatives aimed at providing various services, including diagnostic test reimbursements. These proactive measures by the government are anticipated to further propel the demand for infectious disease molecular diagnostics, thereby driving the overall market growth.
Regional Insights
During the projected period, the Global Infectious Disease Diagnostics Market was dominated by North America. This can be attributed to factors such as rapid urbanization, increased investments by healthcare providers in infrastructure improvement, the need to manage the growing burden of infectious diseases, and government initiatives to improve accessibility of diagnostic services. Europe followed closely behind. Furthermore, changing regulatory requirements for infectious disease testing in the general public contributed to the market's expansion. Moreover, advancements in technology have facilitated the integration of previously manual processes, resulting in the establishment of fully automated systems. As a result, it is anticipated that the Infectious Disease Diagnostics Market in this region will witness substantial growth.
Key Market Players
Biomйrieux SA
Abbott Laboratories Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories Inc.
Danaher Corporation
F. Hoffmann-La Roche AG
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Quidel Corporation
Trinity Biotech PLC
Report Scope:
In this report, the Global Infectious Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Infectious Disease Testing Market, By Product & Service:
- Assays
- Kits
- Reagents
- Instruments
- Services & Software
- Infectious Disease Testing Market, By Technology:
- Molecular Diagnostics
- Immunoassay
- Microbiology
- Others
- Infectious Disease Testing Market, By Disease:
- Hepatitis
- Human Papillomavirus (HPV)
- Human Immunodeficiency Virus (HIV)
- Tuberculosis (TB)
- Hospital-Acquired Infections (HAIs)
- Others
- Infectious Disease Testing Market, By End User:
- Hospital and Clinical Laboratories
- Diagnostic Reference Laboratories
- Academic/Research Institutes
- Others
- Infectious Disease Testing Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in the Global Infectious Disease Testing Market.
Available Customizations:
Global Infectious Disease Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL INFECTIOUS DISEASE TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product & Service (Assays, Kits, Reagents, Instruments, Services & Software)
5.2.2. By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others)
5.2.3. By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others)
5.2.4. By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. NORTH AMERICA INFECTIOUS DISEASE TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Service
6.2.2. By Technology
6.2.3. By Disease
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Infectious Disease Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product & Service
6.3.1.2.2. By Technology
6.3.1.2.3. By Disease
6.3.1.2.4. By End User
6.3.2. Canada Infectious Disease Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product & Service
6.3.2.2.2. By Technology
6.3.2.2.3. By Disease
6.3.2.2.4. By End User
6.3.3. Mexico Infectious Disease Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product & Service
6.3.3.2.2. By Technology
6.3.3.2.3. By Disease
6.3.3.2.4. By End User
7. EUROPE INFECTIOUS DISEASE TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Service
7.2.2. By Technology
7.2.3. By Disease
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Infectious Disease Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product & Service
7.3.1.2.2. By Technology
7.3.1.2.3. By Disease
7.3.1.2.4. By End User
7.3.2. United Kingdom Infectious Disease Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product & Service
7.3.2.2.2. By Technology
7.3.2.2.3. By Disease
7.3.2.2.4. By End User
7.3.3. Italy Infectious Disease Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Product & Service
7.3.3.2.2. By Technology
7.3.3.2.3. By Disease
7.3.3.2.4. By End User
7.3.4. France Infectious Disease Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product & Service
7.3.4.2.2. By Technology
7.3.4.2.3. By Disease
7.3.4.2.4. By End User
7.3.5. Spain Infectious Disease Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product & Service
7.3.5.2.2. By Technology
7.3.5.2.3. By Disease
7.3.5.2.4. By End User
8. ASIA-PACIFIC INFECTIOUS DISEASE TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Service
8.2.2. By Technology
8.2.3. By Disease
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Infectious Disease Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product & Service
8.3.1.2.2. By Technology
8.3.1.2.3. By Disease
8.3.1.2.4. By End User
8.3.2. India Infectious Disease Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product & Service
8.3.2.2.2. By Technology
8.3.2.2.3. By Disease
8.3.2.2.4. By End User
8.3.3. Japan Infectious Disease Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product & Service
8.3.3.2.2. By Technology
8.3.3.2.3. By Disease
8.3.3.2.4. By End User
8.3.4. South Korea Infectious Disease Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product & Service
8.3.4.2.2. By Technology
8.3.4.2.3. By Disease
8.3.4.2.4. By End User
8.3.5. Australia Infectious Disease Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product & Service
8.3.5.2.2. By Technology
8.3.5.2.3. By Disease
8.3.5.2.4. By End User
9. SOUTH AMERICA INFECTIOUS DISEASE TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Service
9.2.2. By Technology
9.2.3. By Disease
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Infectious Disease Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product & Service
9.3.1.2.2. By Technology
9.3.1.2.3. By Disease
9.3.1.2.4. By End User
9.3.2. Argentina Infectious Disease Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product & Service
9.3.2.2.2. By Technology
9.3.2.2.3. By Disease
9.3.2.2.4. By End User
9.3.3. Colombia Infectious Disease Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product & Service
9.3.3.2.2. By Technology
9.3.3.2.3. By Disease
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product & Service
10.2.2. By Technology
10.2.3. By Disease
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Infectious Disease Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product & Service
10.3.1.2.2. By Technology
10.3.1.2.3. By Disease
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Infectious Disease Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product & Service
10.3.2.2.2. By Technology
10.3.2.2.3. By Disease
10.3.2.2.4. By End User
10.3.3. UAE Infectious Disease Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product & Service
10.3.3.2.2. By Technology
10.3.3.2.3. By Disease
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL INFECTIOUS DISEASE TESTING MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Service Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
15.5.1. Biomйrieux SA
15.5.2. Abbott Laboratories Inc.
15.5.3. Becton, Dickinson and Company
15.5.4. Bio-Rad Laboratories Inc.
15.5.5. Danaher Corporation
15.5.6. F. Hoffmann-La Roche AG
15.5.7. Siemens Healthineers AG
15.5.8. Thermo Fisher Scientific Inc.
15.5.9. Quidel Corporation
15.5.10. Trinity Biotech PLC
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL INFECTIOUS DISEASE TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product & Service (Assays, Kits, Reagents, Instruments, Services & Software)
5.2.2. By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others)
5.2.3. By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others)
5.2.4. By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. NORTH AMERICA INFECTIOUS DISEASE TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Service
6.2.2. By Technology
6.2.3. By Disease
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Infectious Disease Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product & Service
6.3.1.2.2. By Technology
6.3.1.2.3. By Disease
6.3.1.2.4. By End User
6.3.2. Canada Infectious Disease Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product & Service
6.3.2.2.2. By Technology
6.3.2.2.3. By Disease
6.3.2.2.4. By End User
6.3.3. Mexico Infectious Disease Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product & Service
6.3.3.2.2. By Technology
6.3.3.2.3. By Disease
6.3.3.2.4. By End User
7. EUROPE INFECTIOUS DISEASE TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Service
7.2.2. By Technology
7.2.3. By Disease
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Infectious Disease Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product & Service
7.3.1.2.2. By Technology
7.3.1.2.3. By Disease
7.3.1.2.4. By End User
7.3.2. United Kingdom Infectious Disease Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product & Service
7.3.2.2.2. By Technology
7.3.2.2.3. By Disease
7.3.2.2.4. By End User
7.3.3. Italy Infectious Disease Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Product & Service
7.3.3.2.2. By Technology
7.3.3.2.3. By Disease
7.3.3.2.4. By End User
7.3.4. France Infectious Disease Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product & Service
7.3.4.2.2. By Technology
7.3.4.2.3. By Disease
7.3.4.2.4. By End User
7.3.5. Spain Infectious Disease Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product & Service
7.3.5.2.2. By Technology
7.3.5.2.3. By Disease
7.3.5.2.4. By End User
8. ASIA-PACIFIC INFECTIOUS DISEASE TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Service
8.2.2. By Technology
8.2.3. By Disease
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Infectious Disease Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product & Service
8.3.1.2.2. By Technology
8.3.1.2.3. By Disease
8.3.1.2.4. By End User
8.3.2. India Infectious Disease Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product & Service
8.3.2.2.2. By Technology
8.3.2.2.3. By Disease
8.3.2.2.4. By End User
8.3.3. Japan Infectious Disease Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product & Service
8.3.3.2.2. By Technology
8.3.3.2.3. By Disease
8.3.3.2.4. By End User
8.3.4. South Korea Infectious Disease Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product & Service
8.3.4.2.2. By Technology
8.3.4.2.3. By Disease
8.3.4.2.4. By End User
8.3.5. Australia Infectious Disease Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product & Service
8.3.5.2.2. By Technology
8.3.5.2.3. By Disease
8.3.5.2.4. By End User
9. SOUTH AMERICA INFECTIOUS DISEASE TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Service
9.2.2. By Technology
9.2.3. By Disease
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Infectious Disease Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product & Service
9.3.1.2.2. By Technology
9.3.1.2.3. By Disease
9.3.1.2.4. By End User
9.3.2. Argentina Infectious Disease Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product & Service
9.3.2.2.2. By Technology
9.3.2.2.3. By Disease
9.3.2.2.4. By End User
9.3.3. Colombia Infectious Disease Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product & Service
9.3.3.2.2. By Technology
9.3.3.2.3. By Disease
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product & Service
10.2.2. By Technology
10.2.3. By Disease
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Infectious Disease Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product & Service
10.3.1.2.2. By Technology
10.3.1.2.3. By Disease
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Infectious Disease Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product & Service
10.3.2.2.2. By Technology
10.3.2.2.3. By Disease
10.3.2.2.4. By End User
10.3.3. UAE Infectious Disease Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product & Service
10.3.3.2.2. By Technology
10.3.3.2.3. By Disease
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL INFECTIOUS DISEASE TESTING MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Service Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
15.5.1. Biomйrieux SA
15.5.2. Abbott Laboratories Inc.
15.5.3. Becton, Dickinson and Company
15.5.4. Bio-Rad Laboratories Inc.
15.5.5. Danaher Corporation
15.5.6. F. Hoffmann-La Roche AG
15.5.7. Siemens Healthineers AG
15.5.8. Thermo Fisher Scientific Inc.
15.5.9. Quidel Corporation
15.5.10. Trinity Biotech PLC
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
